Oxford Vaccine Shows No Signs of Worsening COVID-19 Symptoms

Oxford University has reported positive findings from preclinical animal studies of its potential COVID-19 vaccine ChAdOx1, which involved nine rhesus macaques. However, results from human clinical trials are expected next month.

Preclinical animal studies of COVID-19 vaccine ChAdOx1 found to have positive effects on nine rhesus macaques at the University of Oxford.

The vaccine is currently undergoing human trials as they were performed concurrently with animal testing in order to fast track vaccine development.

First Clinical Trial For COVID-19 Vaccine Approved By Canada
The first Canadian clinical trial for a potential COVID-19 vaccine has been officially approved.

‘The University of Oxford has reported positive findings from preclinical animal studies of its potential COVID-19 vaccine ChAdOx1, which involved nine rhesus macaques. However, results from human clinical trials are expected next month.’

Johanna Swanson, Product Manager at GlobalData, comments:

“The University of Oxford’s recent animal studies for ChAdOx1 showed no signs of worsening disease symptoms. While this may sound like a simple requirement, this is actually an important hurdle for a vaccine to cross. Some previous attempts at coronavirus vaccines for Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in animal models resulted in candidate vaccines that produced side effects such as berserk immune responses, causing lung damage in monkeys and liver damage in ferrets."

“Results from human clinical trials are expected next month for the Oxford University vaccine. GlobalData considers the Oxford University/AstraZeneca’s ChAdOx1 nCoV-19 to a possible front-runner for the Trump administration’s ‘Operation Warp Speed’ - a program aimed at speeding up development of a successful COVID-19 vaccine. Other candidates for the program could include Moderna’s mRNA-1273, Inovio’s INO-4800, Sanofi/GSK’s unnamed vaccine, and Pfizer/BioNTech’s BNT162.”

Coordinated Strategy Fosters Development of Effective COVID-19 Vaccines
A diversity of vaccine approaches must be pursued to meet the global need to protect from the continued threat of the SARS-CoV-2 virus.

Source-Medindia

ICMR, Bharat Biotech Tie Up for COVID-19 Vaccine
ICMR has partnered with Bharat Biotech to develop COVID-19 vaccine. The team will use the virus strain isolated at ICMR's National Institute of Virology (NIV) in Pune.

CSIR Currently Tests COVID-19 Vaccine
The Council of Scientific & Industrial Research (CSIR) is currently testing Cadila Pharmaceuticals' Sepsivac against COVID-19, revealed Phase 2 trial.